ATE42959T1 - Tigogenin-cellobioside und ihr hepta-azetat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die tigogenin- cellobioside enthalten. - Google Patents

Tigogenin-cellobioside und ihr hepta-azetat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die tigogenin- cellobioside enthalten.

Info

Publication number
ATE42959T1
ATE42959T1 AT84304993T AT84304993T ATE42959T1 AT E42959 T1 ATE42959 T1 AT E42959T1 AT 84304993 T AT84304993 T AT 84304993T AT 84304993 T AT84304993 T AT 84304993T AT E42959 T1 ATE42959 T1 AT E42959T1
Authority
AT
Austria
Prior art keywords
tigogenin
cellobiosides
hepta
acetate
processes
Prior art date
Application number
AT84304993T
Other languages
German (de)
English (en)
Inventor
M Rene Malinow
Original Assignee
Oregon Medical Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Medical Res Found filed Critical Oregon Medical Res Found
Application granted granted Critical
Publication of ATE42959T1 publication Critical patent/ATE42959T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Cephalosporin Compounds (AREA)
AT84304993T 1984-04-20 1984-07-23 Tigogenin-cellobioside und ihr hepta-azetat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die tigogenin- cellobioside enthalten. ATE42959T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/602,298 US4602005A (en) 1982-05-17 1984-04-20 Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
EP84304993A EP0159431B1 (en) 1984-04-20 1984-07-23 Tigogenin-cellobioside and its heptaacetate, methods for their preparation, and pharmaceutical compositions containing tigogenin-cellobioside

Publications (1)

Publication Number Publication Date
ATE42959T1 true ATE42959T1 (de) 1989-05-15

Family

ID=24410793

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84304993T ATE42959T1 (de) 1984-04-20 1984-07-23 Tigogenin-cellobioside und ihr hepta-azetat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die tigogenin- cellobioside enthalten.

Country Status (16)

Country Link
US (1) US4602005A (OSRAM)
EP (1) EP0159431B1 (OSRAM)
JP (1) JPS60224697A (OSRAM)
KR (1) KR940002114B1 (OSRAM)
AT (1) ATE42959T1 (OSRAM)
AU (1) AU580005B2 (OSRAM)
CA (1) CA1246544A (OSRAM)
DE (1) DE3478114D1 (OSRAM)
DK (2) DK165839C (OSRAM)
ES (1) ES8601233A1 (OSRAM)
FI (2) FI82253C (OSRAM)
HU (1) HUT37802A (OSRAM)
IE (1) IE58015B1 (OSRAM)
NO (1) NO842990L (OSRAM)
NZ (1) NZ208961A (OSRAM)
ZA (1) ZA845690B (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
WO1993007167A1 (en) * 1991-10-04 1993-04-15 The Procter & Gamble Company Cholesterol lowering compounds and process for making them
CA2079544A1 (en) * 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
HUT67035A (en) * 1991-11-25 1995-01-30 Pfizer New process for the production of steroidal glycosides derivatives
US5294703A (en) * 1992-05-01 1994-03-15 Eastman Kodak Company Process for preparing α-D-cellobiose octaacetate
JPH07504921A (ja) * 1992-06-26 1995-06-01 フアイザー・インコーポレイテツド 高コレステロール血症を治療するためのステロイドグリコシド
WO1994000478A1 (en) * 1992-06-26 1994-01-06 Pfizer Inc. Steroidal beta-o-cellobioside heptaalkanoate process
FI946082A0 (fi) * 1992-06-26 1994-12-23 Pfizer Menetelmä steroidisten perasyyliglykosidien valmistamiseksi
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
BR9406332A (pt) * 1993-04-28 1995-12-26 Pfizer Mono-hidrato cristalino de espirostanil-glicosidal
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
AU7250694A (en) * 1993-06-25 1995-01-17 Biosphere Technologies Inc. Dietary supplement incorporating beta-sitosterol and pectin
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
EP0737203A1 (en) * 1993-12-28 1996-10-16 Pfizer Inc. Steroidal glycosides
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
WO1996009827A2 (en) * 1994-09-20 1996-04-04 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
WO1996038466A1 (en) * 1995-05-29 1996-12-05 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
WO1999048507A2 (en) * 1998-03-26 1999-09-30 Phytopharm Plc Steroidal saponins for treating alzheimer's disease
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
ATE362757T1 (de) * 2001-01-26 2007-06-15 Schering Corp Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
IL156488A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
DK1413331T3 (da) * 2001-01-26 2007-12-10 Schering Corp Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer
AU2002243557B2 (en) * 2001-01-26 2006-01-05 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2434033A1 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
ATE345792T1 (de) * 2001-05-25 2006-12-15 Schering Corp Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer- krankheit
WO2003026643A2 (en) * 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
BR0212907A (pt) * 2001-09-21 2004-10-13 Schering Corp Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
AU2003291719A1 (en) * 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2003300732A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from chlorophytum nimonii
US7160866B2 (en) 2004-03-22 2007-01-09 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from Chlorophytum nimonii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759171A1 (de) * 1977-12-31 1979-07-12 Roecar Holdings Nv Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
US4242502A (en) * 1979-04-20 1980-12-30 United States Of America Enhancement of cholesterol combining properties of saponins
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia

Also Published As

Publication number Publication date
DE3478114D1 (en) 1989-06-15
JPS60224697A (ja) 1985-11-09
EP0159431A3 (en) 1986-01-08
DK165839B (da) 1993-01-25
DK165839C (da) 1993-06-21
NO842990L (no) 1985-10-21
DK14892A (da) 1992-02-06
EP0159431B1 (en) 1989-05-10
JPH0456840B2 (OSRAM) 1992-09-09
IE841904L (en) 1985-10-20
DK361084D0 (da) 1984-07-23
ES534553A0 (es) 1985-11-16
FI842935A0 (fi) 1984-07-23
ES8601233A1 (es) 1985-11-16
US4602005A (en) 1986-07-22
IE58015B1 (en) 1993-06-16
FI87792C (fi) 1993-02-25
FI900531A0 (fi) 1990-02-02
AU580005B2 (en) 1988-12-22
ZA845690B (en) 1986-03-26
KR940002114B1 (ko) 1994-03-17
DK361084A (da) 1985-10-21
FI82253C (fi) 1991-02-11
NZ208961A (en) 1988-01-08
EP0159431A2 (en) 1985-10-30
DK166213B (da) 1993-03-22
AU3097784A (en) 1985-10-24
KR850007432A (ko) 1985-12-04
CA1246544A (en) 1988-12-13
DK14892D0 (da) 1992-02-06
FI82253B (fi) 1990-10-31
HUT37802A (en) 1986-02-28
FI87792B (fi) 1992-11-13
FI842935L (fi) 1985-10-21
DK166213C (da) 1993-08-16

Similar Documents

Publication Publication Date Title
ATE42959T1 (de) Tigogenin-cellobioside und ihr hepta-azetat, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die tigogenin- cellobioside enthalten.
TR199901578T2 (xx) Klaritromisin form 0 kristali
ATE36699T1 (de) Chinonderivate, verfahren zu ihrer herstellung, ihre verwendung und pharmazeutische zusammensetzung.
ES8706717A1 (es) Metodo de preparar esteroides
ZA951227B (en) Camptothecin derivatives and process for their preparation
DE69522589D1 (de) Vitamin D3-Derivate und ein Verfahren zu ihrer Herstellung
EP0027908A3 (en) 2-hydroxyalkyl-3,4,5,trihydroxy piperidines, processes for their preparation and their use as medicaments
ATE8401T1 (de) Anthracyclin-glycoside, verfahren zu ihrer herstellung, zwischenprodukte und ihre herstellung und arzneimittel.
ATE152118T1 (de) Kardioaktive 17b-(3-furyl) und 17b-(4- pyridazinyl)-5beta, 14beta-androstan derivate, verfahren zu ihrer herstellung und pharmazeutische präparate davon
DE3769563D1 (de) Neue derivate von 4,5-dihydro-oxazolen, verfahren zu ihrer herstellung und ihre verwendung.
KR890008156A (ko) 깅콜리드의 신규 알콜시 유도체, 그 제조 방법 및 이를 함유한 치료 조성물
CA2010982A1 (en) Osteogenesis promotion with use of vitamin d derivatives
UA41871C2 (uk) Похідні еритроміцину, спосіб їх одержання та фармацевтична композиція на їх основі
WO1993025568A3 (en) Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
ATE4387T1 (de) Anthracyclin-glycoside, verfahren zu ihrer herstellung und sie enthaltende therapeutische zusammensetzung.
ATE80890T1 (de) Anthracyclinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DE68918597D1 (de) Neues S-Timolol Derivat und Verfahren zu seiner Herstellung.
ATE71107T1 (de) Steroide zur verwendung als mittel gegen krebs und fettsucht, therapeutische zusammensetzungen, die dies enthalten und ihre anwendung zur herstellung einer therapeutischen zusammensetzung.
IL101180A0 (en) Indane derivatives,their preparation and their use as fragrance materials
EP0367671A3 (en) Novel beta-d-phenylthioxylosides, their method of preparation and their use as pharmaceuticals
ATE96803T1 (de) Indolo(3,2,1-de>(1,4>-oxazino(2,3,4ij>(1,5>naphthyridinderivate, verfahren zu ihrer herstellung und zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende zubereitungen.
KR910000780A (ko) 신규 안트라사이클린 및 그 제조방법과 이것을 포함한 의약품
JPS5576864A (en) Carbostyril derivative
ES2112597T3 (es) Nuevos derivados de 17-(3-imino-2-alquil-propenil)-5beta,14beta-androstano activos sobre el sistema cardiovascular, procesos para su preparacion y composiciones farmaceuticas que contienen los mismos.
JPS5649360A (en) 2-oxoquinoline derivative

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee